<p>Cytek Biosciences（纳斯达克代码：CTKB - 获取免费报告）于周三发布了其财报。该公司报告本季度每股收益为（$0.04），低于市场共识预期的$0.01，差距为（$0.05），FiscalAI 报道。该公司本季度的收入为 5229 万美元，而分析师预期为 5149 万美元。Cytek Biosciences 的净利润率为负 3.27%，股本回报率为负 1.66%。Cytek Biosciences 更新了其 2025 财年的每股收益指引。</p>
<p>获取 <strong>Cytek Biosciences</strong> 的提醒：</p>
<h2>Cytek Biosciences 股票表现</h2>
<p>周三午盘交易中，纳斯达克代码：CTKB 的股票上涨了$0.10，达到了$4.01。该公司的交易量为 956,227 股，而其平均交易量为 970,038 股。Cytek Biosciences 的 1 年最低价为$2.37，1 年最高价为$7.63。该公司的 50 日简单移动平均为$3.92，200 日简单移动平均为$3.60。该公司的市值为 5.1017 亿美元，市盈率为-80.20，贝塔值为 1.33。</p>
<h2>对 Cytek Biosciences 的对冲基金看法</h2>
<p>对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Federated Hermes Inc.在第二季度将其在 Cytek Biosciences 的持股增加了 150.9%。Federated Hermes Inc.现在拥有 7221 股该公司的股票，价值$25,000，此前在此期间购买了额外的 4343 股。Captrust Financial Advisors 在第二季度获得了 Cytek Biosciences 的新股份，价值约$43,000。Tower Research Capital LLC TRC 在第二季度将其在 Cytek Biosciences 的持股增加了 338.1%。Tower Research Capital LLC TRC 现在拥有 19760 股该公司的股票，价值$67,000，此前在此期间获得了额外的 15250 股。Quantbot Technologies LP 在第二季度获得了 Cytek Biosciences 的新股份，价值约$84,000。最后，Strs Ohio 在第一季度获得了 Cytek Biosciences 的新股份，价值约$105,000。机构投资者和对冲基金持有该公司 69.46% 的股票。</p>
<h2>分析师设定新目标价</h2>
<p>一些研究分析师最近对该股票进行了评论。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Cytek Biosciences 股票的 “卖出（e+）” 评级。Zacks Research 在 10 月 6 日的研究报告中将 Cytek Biosciences 的股票评级从 “持有” 上调至 “强力买入”。一位股票研究分析师给予该股票 “强力买入” 评级，两位给予 “买入” 评级，两位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，共识目标价为$5.60。</p>
<p><strong>查看我们关于 CTKB 的最新研究报告</strong></p>
<h2>关于 Cytek Biosciences</h2>
<p>（获取免费报告）</p>
<p>Cytek Biosciences, Inc 是一家细胞分析解决方案公司，提供细胞分析工具，以促进生物医学研究和临床应用的科学进步。它提供 aurora 和 northern lights 系统，这些是光谱流式细胞仪，通过利用多个激光的荧光特征来区分单个细胞上的荧光标签，从而提供细胞分析；以及 aurora 细胞分选系统，利用全光谱分析技术进一步拓宽细胞分析的潜在应用；aurora CS 系统；amnis imagestream 成像流式细胞仪；guava muse 细胞分析仪；guava easycyte 流式细胞仪；以及 orion 试剂鸡尾酒制备系统。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Cytek Biosciences</li>
<li>标普 500 股票向投资者传达了什么市场信息？</li>
<li>目前现金充裕的三只高增长潜力股票</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>为什么 Vertical Aerospace 股票在这次飞行测试后可能会翻倍</li>
<li>如何使用股票筛选器寻找股票</li>
<li>亚马逊：突破确认——接下来可能会去哪里</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RLQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RLQg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Cytek Biosciences 吗？</h2>
<p>在你考虑 Cytek Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Cytek Biosciences 并不在名单上。</p>
<p>虽然 Cytek Biosciences 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CTKB

<p>Cytek Biosciences（纳斯达克代码：CTKB）公布了季度财报，每股收益（EPS）为（$0.04），低于市场共识预期的$0.01。收入为$52.29 百万，超过预期的$51.49 百万。该公司的股本回报率为负 1.66%，净利润率为 3.27%。分析师对该股票的评级不一，市场共识评级为 “持有”，目标价为$5.60。机构投资者持有该公司 69.46% 的股份，近期交易中股价上涨至$4.01</p>

<p>Cytek Biosciences (NASDAQ:CTKB - Get Free Report) released its earnings results on Wednesday. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.05), FiscalAI reports. The company had revenue of $52.29 million for the quarter, compared to analyst estimates of $51.49 million. Cytek Biosciences had a negative net margin of 3.27% and a negative return on equity of 1.66%. Cytek Biosciences updated its FY 2025 guidance to EPS.</p>
<div class="lb-trans"><p>Cytek Biosciences（纳斯达克代码：CTKB - 获取免费报告）于周三发布了其财报。该公司报告本季度每股收益为（$0.04），低于市场共识预期的$0.01，差距为（$0.05），FiscalAI 报道。该公司本季度的收入为 5229 万美元，而分析师预期为 5149 万美元。Cytek Biosciences 的净利润率为负 3.27%，股本回报率为负 1.66%。Cytek Biosciences 更新了其 2025 财年的每股收益指引。</p>
</div><p>Get <strong>Cytek Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cytek Biosciences</strong> 的提醒：</p>
</div><h2>Cytek Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Cytek Biosciences 股票表现</h2>
</div><p>Shares of NASDAQ:CTKB traded up $0.10 during midday trading on Wednesday, reaching $4.01. The company had a trading volume of 956,227 shares, compared to its average volume of 970,038. Cytek Biosciences has a 1-year low of $2.37 and a 1-year high of $7.63. The company has a fifty day simple moving average of $3.92 and a two-hundred day simple moving average of $3.60. The firm has a market cap of $510.17 million, a price-to-earnings ratio of -80.20 and a beta of 1.33.</p>
<div class="lb-trans"><p>周三午盘交易中，纳斯达克代码：CTKB 的股票上涨了$0.10，达到了$4.01。该公司的交易量为 956,227 股，而其平均交易量为 970,038 股。Cytek Biosciences 的 1 年最低价为$2.37，1 年最高价为$7.63。该公司的 50 日简单移动平均为$3.92，200 日简单移动平均为$3.60。该公司的市值为 5.1017 亿美元，市盈率为-80.20，贝塔值为 1.33。</p>
</div><h2>Hedge Funds Weigh In On Cytek Biosciences</h2>
<div class="lb-trans"><h2>对 Cytek Biosciences 的对冲基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Federated Hermes Inc. boosted its stake in Cytek Biosciences by 150.9% in the 2nd quarter. Federated Hermes Inc. now owns 7,221 shares of the company's stock worth $25,000 after purchasing an additional 4,343 shares during the period. Captrust Financial Advisors acquired a new stake in Cytek Biosciences during the 2nd quarter worth about $43,000. Tower Research Capital LLC TRC boosted its position in Cytek Biosciences by 338.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 19,760 shares of the company's stock worth $67,000 after acquiring an additional 15,250 shares during the period. Quantbot Technologies LP acquired a new stake in Cytek Biosciences during the 2nd quarter worth about $84,000. Finally, Strs Ohio acquired a new stake in shares of Cytek Biosciences during the first quarter worth approximately $105,000. Institutional investors and hedge funds own 69.46% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Federated Hermes Inc.在第二季度将其在 Cytek Biosciences 的持股增加了 150.9%。Federated Hermes Inc.现在拥有 7221 股该公司的股票，价值$25,000，此前在此期间购买了额外的 4343 股。Captrust Financial Advisors 在第二季度获得了 Cytek Biosciences 的新股份，价值约$43,000。Tower Research Capital LLC TRC 在第二季度将其在 Cytek Biosciences 的持股增加了 338.1%。Tower Research Capital LLC TRC 现在拥有 19760 股该公司的股票，价值$67,000，此前在此期间获得了额外的 15250 股。Quantbot Technologies LP 在第二季度获得了 Cytek Biosciences 的新股份，价值约$84,000。最后，Strs Ohio 在第一季度获得了 Cytek Biosciences 的新股份，价值约$105,000。机构投资者和对冲基金持有该公司 69.46% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of research analysts recently commented on the stock. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Cytek Biosciences in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Cytek Biosciences from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Monday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $5.60.</p>
<div class="lb-trans"><p>一些研究分析师最近对该股票进行了评论。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Cytek Biosciences 股票的 “卖出（e+）” 评级。Zacks Research 在 10 月 6 日的研究报告中将 Cytek Biosciences 的股票评级从 “持有” 上调至 “强力买入”。一位股票研究分析师给予该股票 “强力买入” 评级，两位给予 “买入” 评级，两位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，共识目标价为$5.60。</p>
</div><p><strong>Check Out Our Latest Research Report on CTKB</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CTKB 的最新研究报告</strong></p>
</div><h2>About Cytek Biosciences</h2>
<div class="lb-trans"><h2>关于 Cytek Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.</p>
<div class="lb-trans"><p>Cytek Biosciences, Inc 是一家细胞分析解决方案公司，提供细胞分析工具，以促进生物医学研究和临床应用的科学进步。它提供 aurora 和 northern lights 系统，这些是光谱流式细胞仪，通过利用多个激光的荧光特征来区分单个细胞上的荧光标签，从而提供细胞分析；以及 aurora 细胞分选系统，利用全光谱分析技术进一步拓宽细胞分析的潜在应用；aurora CS 系统；amnis imagestream 成像流式细胞仪；guava muse 细胞分析仪；guava easycyte 流式细胞仪；以及 orion 试剂鸡尾酒制备系统。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Cytek Biosciences</li>
<li>What Do S&amp;P 500 Stocks Tell Investors About the Market?</li>
<li>3 Cash-Rich Stocks With High Growth Potential Right Now</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Why Vertical Aerospace Stock Could Double After This Flight Test</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>Amazon: Breakout Confirmed—Here’s Where It Could Go Next</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Cytek Biosciences</li>
<li>标普 500 股票向投资者传达了什么市场信息？</li>
<li>目前现金充裕的三只高增长潜力股票</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>为什么 Vertical Aerospace 股票在这次飞行测试后可能会翻倍</li>
<li>如何使用股票筛选器寻找股票</li>
<li>亚马逊：突破确认——接下来可能会去哪里</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RLQg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CTKB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cytek Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Cytek Biosciences 吗？</h2>
</div><p>Before you consider Cytek Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Cytek Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytek Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Cytek Biosciences 并不在名单上。</p>
</div><p>While Cytek Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cytek Biosciences 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cytek Biosciences（纳斯达克股票代码：CTKB）公布季度收益结果